Search results

  1. V.R.T.

    Daratumumab, isatuximab (CD38 drugs)

    That does sound very ambitious. If it wasn't for her apparantly saying they want to start at the same time I'd say that meant they were starting AIM ME before PIONEER. Which frankly sounds like a better plan than stalling until the CD19/20 trials can go ahead.
  2. V.R.T.

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    This particular monoclonal is made by Sanofi, who recently agreed to let Scheibenbogen trial their CD38 inhibitor in ME/CFS. So if there is a rationale for trying their OX40 monoclonal in ME they might well be amenable.
  3. V.R.T.

    UK House of Lords/ House of Commons - relevant people and questions

    And then use the publicity to get even more funding for services that don't help anybody!
  4. V.R.T.

    UK House of Lords/ House of Commons - relevant people and questions

    That would be useful to have for future reference if anyone does find it!
  5. V.R.T.

    UK House of Lords/ House of Commons - relevant people and questions

    This is absolutely sickening. They've sewed up both sides of this 'debate'. It all seems so nice and cosy until you consider what these people have done. The cost of this catastrophic failure to provide any appropriate services for pwME. The research that hasnt happened because we have perfectly...
  6. V.R.T.

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    Yes if anyone knows of any other lupus researchers (than the kings people) who are any good, perhaps letting them know about the Nov. 6 event might be an idea.
  7. V.R.T.

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    In her recent talk Michelle James lists OX40 as a PET tracer that is being investigated in ME. In my email I asked if it was her or someone else studying it but I haven't heard back yet. I know I've been a broken record about these tracers lately but it's an interesting connection!
  8. V.R.T.

    CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies, 2024, Huang et al.

    I've now emailed her. Hopefully I hear back. I find this whole tracer business so facinating!
  9. V.R.T.

    Is the key pathology of ME/CFS in bone marrow?

    So apparantly (repeating myself from another thread here) according to Michelle James' Stanford talk, someone (it wasn't clear which group) is looking at OX40, a CD4 and CD8 T Cell marker, in a PET study. If that can show the bone marrow, perhaps that might give us some clues?
  10. V.R.T.

    CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies, 2024, Huang et al.

    Thank you!
  11. V.R.T.

    Community Symposium on the Molecular Basis of ME/CFS Sept 5 (Stanford/Ron Davis)

    In Michelle James' talk she mentioned - in the list of tracers that various groups have been looking at in ME/CFS - that there is a CD4/CD8 T cell marker called OX40. I don't know if it's her lab or someone else looking at OX40 but I would be very interested to see what the results of that are.
  12. V.R.T.

    CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies, 2024, Huang et al.

    I hadn't thought about the fact it might not necessarily be involved because its high- good point. Ah that sounds like it could be complicated. I drafted an email to Michelle James yesterday but looking now she doesn't seem to have a contact email listed on her Stanford page. I was also...
  13. V.R.T.

    CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies, 2024, Huang et al.

    @MelbME you are running PET studies on ME/CFS patients currently right? Have you considered/would you consider doing a further study using this tracer in order to follow up on your CD38 finding in your study with Jo Cambridge?
  14. V.R.T.

    Is the key pathology of ME/CFS in bone marrow?

    Perhaps someone should contact Michelle James about this then. If she isn't interested in studying cd38 herself she may be able to advise how best to go about it.
  15. V.R.T.

    United Kingdom: Dr Suzanne O’Sullivan (BPS neurologist)

    A lot of ableists are obsessed with the idea you shouldn't let your disablity define you, and would probably say yes.
  16. V.R.T.

    Is the key pathology of ME/CFS in bone marrow?

    Just found out that there are cd38 PET tracers - would these be useful for exploring this hypothesis?
  17. V.R.T.

    CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies, 2024, Huang et al.

    Would these tracers be useful for exploring the hypothesis that CD38 is integral to the pathology of ME/CFS?
  18. V.R.T.

    Is the key pathology of ME/CFS in bone marrow?

    Yes I think I know the exact type of pain you mean. It does often seem to come from inside the bone, if that is possible.
  19. V.R.T.

    MRC/NIHR DecodeME Showcase meeting online and in person Nov 6th

    Yes that really shows a lack of initiative/interest on their part.
  20. V.R.T.

    Is the key pathology of ME/CFS in bone marrow?

    So if we were convinced the pathology was partly in the bone marrow in ME/CFS, what would the next steps be?
Back
Top Bottom